Genentech, Inc.

Syros Pharmaceuticals, Inc.

F. Hoffmann-la Roche Ag

Robin Larouche-Gauthier

Francis Beaumier

Luce Lépissier

Huifen Chen

Matthew Volgraf

Elisia Villemure

Stephane Ciblat

Yi Zhang

Kevin Sprott

Jason J Marineau

Lea Constantineau-Forget

Jack Alexander Terrett

Lauren Berstler

Christopher Roberts

Boubacar Sow

Claudio F Sturino

Peter B Rahl

Chantal Grand-Maître

Martin Déry

Stuart Ward

Daniel Shore

Aijun Lu

Martin Dery

Bing-Yan Zhu

Jun Liang

Brian Salvatore Safina

Xiaojing Wang

Georgette M Castanedo

Andrew Peter Cridland

Jason R Zbieg

Chantal Grand-Maitre

Malcolm Huestis

Baihua Hu

Lisa Marie Barton

Peter B Rahi

Michael John Lambrecht

Araz Jakalian

Fabio Broccatelli

Man Un Ung

Arun Yadav

Andrew Cridland

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R, Rand n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Oxadiazole transient receptor potential channel inhibitors

A compound, of formula (I): suitable for treating a cancer wherein the cancer is susceptible to inhibition of Cbl-B.

Lactams as CBL-B inhibitors selective over C-CBL

The present invention provides novel compounds of Formulas (I) and (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.

Compounds for the modulation of Myc activity

The invention relates to methods of using compounds formula I: and pharmaceutically acceptable salts thereof wherein A, X, R, Rand n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angiogenesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject. 

Compounds for the modulation of MYC activity

The present invention provides novel compounds of Formulas (I) and (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject. 

The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.

Oxadiazolones as transient receptor potential channel inhibitors

The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject. 

Compounds for the modulation of myc activity

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Growing community of inventors

Montreal, Canada

Robin Larouche-Gauthier